The global small animal imaging market is anticipated to grow at a CAGR of 8.79% between 2019 to 2027 to generate revenue of $4,854 million by 2027. Protein labelling is an effective tool for studying protein structure and function. The small animal imaging market is primarily driven by the following factors:

• Growing usage of multimodal imaging instruments
• The rise in the pharmaceutical industry and R&D expenditures
• Rise in the adoption of non-invasive technology for small animal imaging

The important drivers increasing growth in the global small animal imaging market is the growing usage of multimodal imaging instruments and rise in the pharmaceutical industry and R&D expenditures. The ongoing evolution of imaging technology has witnessed rapid growth in the development and use of multimodal imaging instruments. Rising R&D expenditures by pharmaceutical companies is a direct consequence of changing industry structure, specifically the expansion of the biotechnology segment.

The applications of small animal imaging market is used extensively for various purposes. Small animal imaging system and reagents have extensive applications in the oncology area and the upsurge in cases of cancers across the globe. The increasing prevalence of cardiovascular diseases is expected to positively influence the growth of the global small animal imaging market in the cardiology application area. The use of animal models has contributed to increasing understanding, and offering novel approaches focused on increasing the treatment and the diagnostic. An autoimmune disease is a disorder arising from an irregular immune response to usual body cells. The rising prevalence of various neurodegenerative disorders is driving the market growth. The growing prevalence of various neurodegenerative disorders is likely to propel the adoption of MRI imaging, as these systems are used for the diagnosis of brain and neurological disorders.

Stringent regulation is one of the major factors hindering the small animal imaging market. The regulatory bodies of different countries have different sets of rules for the implementation of medical devices, thus creating an ambiguous situation for the product manufacturers, since the lack of common standards can turn a product useless if it gets certified in one country and not be fit for certification in another country.

The global small animal imaging market segments include application, modality, and reagent.

Application is segmented into:

• Neurology and psychiatry
• Oncology
• Autoimmune Diseases
• Cardiology
• Other Application

Modality is segmented into:

• Optical imaging system
• Nuclear imaging system
• Micro MRI
• Micro CT
• Micro Ultrasound
• Photoacoustic imaging systems
• Magnetic Particle Imaging System

Reagent is segmented into:

• Optical imaging Reagent
• Nuclear imaging Reagents
• MRI Contrasts Reagents
• Ultrasound Contrast Reagents
• CT Contrast Reagents

This report covers the present market conditions and the growth prospects of the global small animal imaging market for 2019-2027 and considered the revenue generated through the sales of small animal imaging for application, modality, and reagent to calculate the market size by considering 2018 as the base year.

Geographically, the global small animal imaging market has been segmented on the basis of four major regions, which include:

• North America Small Animal Imaging Market: The United States & Canada
• Asia-Pacific Small Animal Imaging Market: China, India, Japan, Australia, South Korea & Rest of APAC
• Europe Small Animal Imaging Market: The United Kingdom, France, Germany, Italy, Spain & Rest of Europe
• Rest of World: Latin America & Middle East and Africa

The small animal imaging market in North America is expected to hold the largest share by 2027 because of the possibilities of technological development within imaging solutions, the increasing demand for precision medicine and treatment due to the increasing number of medical conditions such as cancer, cardiovascular, neurological disorders, etc. North America small animal imaging market constitutes approximately 41% share. The region has the top exporters of small animal imaging devices and spare parts across the globe.

On the other hand, the Asia Pacific market is anticipated to be the fastest-growing region for the small animal imaging techniques and appliances. Asia Pacific is a highly lucrative market for small animal imaging device manufacturers, owing to the availability of a large skilled labor base and improving healthcare infrastructure in terms of advanced imaging devices. Asia Pacific small animal imaging market is expected to be on up-surging trend owing to proactive government initiatives to support the R&D to develop novel drugs and medication using new small animal imaging tests.

The small animal imaging market is segmented based on modality which is sub-divided into Optical imaging system, Nuclear imaging system, Micro MRI, Micro CT, Micro-Ultrasound, Photoacoustic imaging systems and Magnetic Particle Imaging System. On the basis of reagent, the sub-division goes into Optical imaging Reagent, Nuclear imaging Reagents, MRI Contrasts Reagents, Ultrasound Contrast Reagents and CT Contrast Reagents. One of the modalities in pre-clinical imaging is optical imaging, which involves the use of fluorescent and bioluminescent probes and reporters for the concurrent interrogation of the sub-molecular and molecular events and to monitor a disease progression in small animal models. Micro-ultrasound is an important imaging method for preclinical applications. Magnetic particle imaging is an emerging tomographic technique with the potential for simultaneous high-resolution. MRI contrast reagents are employed to enhance the visibility of internal body structures in MRI. Contrast materials, also named as contrast media or contrast agents, are employed to improve pictures of internal structure of the body generated by computed tomography (CT).

The major market players of the global small animal imaging market are:

• Fujifilm Holdings Corporation
• MILabs B.V.
• Aspect Imaging
• Olympus Corporation
• Siemens Healthcare GmbH

Company profiles covers the analysis of important players. Fujifilm Holdings Corporation was founded in 1934 and is headquartered in Tokyo, Japan. FUJIFILM Holdings Corporation develops, produces, sells, and services imaging, information, and document solutions worldwide. Siemens Healthineers, Inc. is a manufacturer and producer of clinical diagnostics and therapeutic systems. With respect to the diagnostic imaging market, the company primarily offers a wide range of medical imaging units for efficient diagnosis of chronic disorders.

Key Findings of the global small animal imaging market:

• Nuclear imaging system holds the largest market share in terms of modality
• Oncology is the fastest growing application during the forecast period
• Optical imaging reagent is anticipated to grow significantly during the forecast period

dures are performed in various departments that include inpatient department (IPD) and outpatient department (OPD), hospital wards, cardiac centres, and others. The research laboratories use POC diagnostic devices in the research process, which includes clinical trials of various new drugs and medical devices. The home care End-user of POC diagnostic devices increases steadily due to an increase in awareness about personalized healthcare and the importance of continuous monitoring in the management of some diseases like diabetes. Prescription based devices are mostly preferred due to the ensured safety and their effective use in the treatment of various diseases. Increase in demand for the OTC glucose monitoring devices for the management of diabetes is the major factor to drive the growth of this market.

The major market players of the global point of care diagnostic market are:

• Abbott
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Cardinal Health Inc.

Company Profiles covers the analysis of important players. Abbott Diagnostic is a US-based medical equipment manufacturer company, headquartered in Illinois. Abbot diagnostic, a manufacturer of in vitro diagnostics, offers a range of medical instruments, tests, and systems for clinics and hospitals. Cardinal Health has a diverse portfolio of pharmaceutical and medical-surgical products. Its pharmaceutical products include retail products and mail-order facilities at hospitals and physician offices. The surgical product portfolio comprises products for ambulatory care, clinical laboratories, hospitals, and physicians.

Key Findings of the global point of care diagnostic market:

• Infectious disease testing kit is the fastest growing product type during the forecast period.
• Professional diagnostic centers are the major end-user in point of care market.
• Prescription based devices are the frequently used mode of prescription.